Candriam Luxembourg S.C.A. Lowers Position in Replimune Group, Inc. (NASDAQ:REPL)

Candriam Luxembourg S.C.A. trimmed its stake in Replimune Group, Inc. (NASDAQ:REPLGet Rating) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 519,512 shares of the company’s stock after selling 2,629 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Replimune Group were worth $14,079,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company grew its holdings in Replimune Group by 3.0% in the third quarter. The Manufacturers Life Insurance Company now owns 15,945 shares of the company’s stock valued at $473,000 after purchasing an additional 470 shares during the period. Voya Investment Management LLC grew its stake in Replimune Group by 5.6% during the third quarter. Voya Investment Management LLC now owns 11,071 shares of the company’s stock worth $328,000 after buying an additional 587 shares during the period. Royal Bank of Canada grew its stake in Replimune Group by 15.8% during the third quarter. Royal Bank of Canada now owns 4,804 shares of the company’s stock worth $143,000 after buying an additional 657 shares during the period. Credit Suisse AG grew its stake in Replimune Group by 5.2% during the third quarter. Credit Suisse AG now owns 14,994 shares of the company’s stock worth $445,000 after buying an additional 744 shares during the period. Finally, Deutsche Bank AG grew its stake in Replimune Group by 1.4% during the third quarter. Deutsche Bank AG now owns 89,198 shares of the company’s stock worth $2,644,000 after buying an additional 1,210 shares during the period. Hedge funds and other institutional investors own 75.42% of the company’s stock.

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Replimune Group from $47.00 to $39.00 and set an “overweight” rating for the company in a research note on Monday, April 4th. BMO Capital Markets decreased their price objective on shares of Replimune Group from $51.00 to $30.00 and set an “outperform” rating for the company in a research note on Friday, March 18th. Finally, Zacks Investment Research upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $48.33.

REPL stock opened at $15.49 on Wednesday. The company has a current ratio of 23.39, a quick ratio of 23.39 and a debt-to-equity ratio of 0.06. Replimune Group, Inc. has a 1-year low of $13.05 and a 1-year high of $40.22. The firm has a fifty day moving average price of $16.84 and a two-hundred day moving average price of $21.95.

In other news, major shareholder Fund Iv L.P. Omega sold 16,500 shares of the company’s stock in a transaction dated Monday, March 14th. The shares were sold at an average price of $15.42, for a total transaction of $254,430.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 40.30% of the stock is owned by insiders.

Replimune Group Company Profile (Get Rating)

Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.

See Also

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPLGet Rating).

Institutional Ownership by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.